Discovery of Novel Highly Potent Hepatitis C Virus NS5A Inhibitor (AV4025)

A series of next in class small-molecule hepatitis C virus (HCV) NS5A inhibitors with picomolar potency containing 2-pyrrolidin-2-yl-5-{4-[4-(2-pyrrolidin-2-yl-1<i>H</i>-imidazol-5-yl)­buta-1,3-diynyl]­phenyl}-1<i>H</i>-imidazole cores was designed based on the SAR studies available for the reported NS5A inhibitors. Compound <b>13a</b> (AV4025), with (<i>S</i>,<i>S</i>,<i>S</i>,<i>S</i>)-stereochemistry (EC₅₀ = 3.4 ± 0.2 pM, HCV replicon genotype 1b), was dramatically more active than were the compounds with two (<i>S</i>)- and two (<i>R</i>)-chiral centers. Human serum did not significantly reduce the antiviral activity (<4-fold). Relatively favorable pharmacokinetic features and good oral bioavailability were observed during animal studies. Compound <b>13a</b> was well tolerated in rodents (in mice, LD₅₀ = 2326 mg/kg or higher), providing a relatively high therapeutic index. During safety, pharmacology and subchronic toxicity studies in rats and dogs, it was not associated with any significant pathological or clinical findings. This compound is currently being evaluated in phase I/II clinical trials for the treatment of HCV infection